Entering text into the input field will update the search result below

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep. 12, 2022 6:48 AM ETClovis Oncology, Inc. (CLVSQ) StockBy: Ravikash Bakolia, SA News Editor5 Comments

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff

  • Clovis Oncology (NASDAQ:CLVS) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer.
  • The company presented data from a subgroup analysis of a monotherapy comparison in the phase 3 trial

Recommended For You

Related Stocks

SymbolLast Price% Chg
CLVSQ--
Clovis Oncology, Inc.